Plain-English translation of NCT07672756 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called given as a subcutaneous injection (under the skin) in adults with phenylketonuria, a genetic condition that makes it hard for the body to process a protein building block called phenylalanine. Researchers want to understand how safe the medication is, how well people tolerate it, and how the body processes it. This is an early-stage study (Phase 1), meaning it's the first time this treatment is being tested in humans.
Phenylketonuria requires careful management throughout life, and current treatment options have limitations. Researchers developed this medication to offer a new way to help manage the condition by targeting the underlying genetic problem.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In Phase 1a, you would receive a single injection under the skin and then be monitored for 4 weeks (the whole phase lasts about 6 weeks). In Phase 1b (if you're enrolled in that part), you would receive injections once a week for 4 weeks. Throughout both phases, you'll have regular check-ups to monitor your safety, blood work to see how your body handles the medication, and assessments of how well you tolerate the injections. The trial includes a 2-week screening period before you start receiving the medication.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China